VELOXIS PHARMACEUTICALS A/S: Financial statements 2023
CVR: 26527767
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2023. Equity in the 2023 report amounted to USD 2,778,000. The solvency ratio was 82.5%. The company had 1 employee in the financial year.
- Equity
- USD 2,778,000
- Total Assets
- USD 3,367,000
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | - | 2.8M USD | 1 |
| 2022 | 0 USD | 0 USD | 2.1M USD | 2.9M USD | - |
| 2021 | 45.3M USD | 45.3M USD | 1.1B USD | 1.3B USD | - |
| 2018 | 39.5M USD | 31.6M USD | -5.3M USD | 4.6M USD | - |
| 2017 | 30.2M USD | 25M USD | -9.5M USD | 5.3M USD | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of May 22, 2023, Keigo Nakatsukasa has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of May 22, 2023, Hideo Hikami has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
About VELOXIS PHARMACEUTICALS A/S
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.
